Ofatumumab may slow brain loss and protect thinking

Credibility

Interest

Share:2 min read

Key Takeaway

In people with relapsing MS, treatment with ofatumumab slowed how fast the brain shrinks and was linked with stable or improved thinking skills for many patients over time.

What They Found

Researchers followed 85 people with relapsing MS on ofatumumab and scanned their brains and tested thinking over time. The brain continued to shrink (called atrophy), but the rate of shrinking slowed after about a year, like a leaking balloon that starts losing air more slowly. On thinking tests, people on average got better scores over time, especially in how fast they process information and in memory. When looking at the whole group, changes in brain size did not clearly match changes in thinking for everyone. However, in people who were already more disabled or who had worse thinking at the start, sharper shrinkage in key brain areas was linked to worse thinking later on.

Who Should Care and Why

People with relapsing MS should care because this suggests ofatumumab may help slow brain tissue loss and protect thinking skills, which matters for daily tasks like remembering appointments or following conversations. Caregivers may notice that loved ones could keep or improve mental speed and memory, especially during the first year of treatment. Healthcare providers can use this information to discuss expectations: treatment may slow damage but not stop it completely, and some patients stay at higher risk. The findings most directly help patients with milder disability or those starting with better thinking, but also highlight that people who are already more impaired need close monitoring. Think of it like a walking aid that slows a fall rather than stopping it entirely — it helps many people but some still need extra support.

Important Considerations

This was an observational study, not a randomized trial, so we can’t be sure of cause and effect — other factors might have helped the brain or thinking. The group was relatively young and mostly had relapsing MS, so results may not apply to everyone with MS, such as older adults or those with progressive forms. Brain scans and thinking tests don’t capture every part of daily life, so individual results may vary and should be discussed with your healthcare team.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates MS Diagnostics MS Progression

Article Topics:

Brain atrophyCognitive impairmentMultiple sclerosisNeurodegenerationOfatumumab

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News